Form 4: Redmile Group Reorganizes Fate Therapeutics Holdings

Redmile Group, LLC has completed an internal reorganization of its holdings in Fate Therapeutics Inc, transferring over 8.9 million shares and various derivative securities to subsidiary entities.

Summary

• RedCo II Master Fund, L.P. distributed its entire holding of Fate Therapeutics securities to two wholly-owned special purpose vehicles (SPVs).
• The transaction involved the transfer of 8,977,624 shares of common stock for no consideration.
• Derivative securities transferred include 3,691,324 pre-funded warrants and 162,013 shares of Class A Convertible Preferred Stock.
• The Class A Preferred Stock is convertible into 810,065 shares of common stock based on a conversion price of $2.66.
• Cash-settled swap agreements representing 266,280 notional shares were novated to the SPVs at a reference price of $3.02.
• RedCo II Master Fund, L.P. will be dissolved following this distribution and ceases to be a 10% owner.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event. While the reporting entity is changing, the core institutional support from Redmile Group remains constant.

Positives

• Aggregate beneficial ownership by Redmile Group and its principal, Jeremy Green, remains unchanged, signaling continued commitment.
• The reorganization was conducted for no consideration, avoiding market-based sell-off pressure.
• Institutional backing remains strong with over 12.8 million shares held indirectly by Redmile-managed vehicles.

Negatives

• The dissolution of RedCo II Master Fund, L.P. as a direct reporting entity may slightly complicate the tracking of specific fund-level movements for outside analysts.

Risks

• Beneficial ownership is restricted by a 14.99% cap on the combined voting power, which limits the immediate exercise of all warrants and preferred stock.
• The use of cash-settled swaps involves counterparty risk and does not grant direct voting or dispositive control over the underlying shares.

Future Outlook

The reporting persons maintain a significant long-term investment position in the company. The reorganization suggests a structural optimization of investment vehicles rather than a change in strategic outlook or intent to exit the position.

Management Comments

• The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green.
• RedCo II no longer has voting or dispositive power over such securities and is no longer a beneficial owner of more than 10% of the Issuer's Common Stock.

Industry Context

StockSavvy.ai notes that large-scale internal reorganizations by biotech-focused investment firms like Redmile Group are common when funds reach the end of their lifecycle or when optimizing for tax and regulatory efficiency. This activity is typically neutral for the issuer's operational trajectory.

Comparison to Industry Standards

• The use of pre-funded warrants to maintain economic exposure while staying below ownership caps is a standard strategy used by institutional investors like Perceptive Advisors and Baker Bros. Advisors.
• The 14.99% ownership blocker is a common governance feature in private investment in public equity (PIPE) transactions within the biotechnology sector to avoid triggering 'poison pill' provisions or change-of-control clauses.

Corporate Governance

Related Party Transactions

• Pro rata distribution of common stock, warrants, and preferred stock from RedCo II to its wholly-owned subsidiaries for no consideration.

Stakeholder Impact

• Shareholders: No immediate impact as the reorganization does not involve market sales or dilution.
• Regulators: RedCo II exits as a direct 10% reporting owner, though the parent group remains a major stakeholder.

Next Steps

• Formal dissolution of RedCo II Master Fund, L.P.
• Continued reporting of holdings through Redmile Group's subsidiary SPVs.

Key Dates

Recommendation

The filing details a neutral administrative reorganization of a major shareholder's position. Because there is no change in the actual economic interest or voting power held by Redmile Group, it does not provide a new buy or sell signal for the stock.

Keywords

Fate Therapeutics, FATE, Redmile Group, Jeremy Green, Insider Trading, Form 4, Biotechnology, Convertible Preferred Stock, Pre-funded Warrants, Equity Swaps